High ST6GAL1 expression promotes an immune‐activated tumor microenvironment (TME), characterized by increased infiltration of CD8+ T cells and M1 macrophages, thereby improving sensitivity to immunotherapy. The gene discussed is ST6GAL1; the disease is neoplasm.